8-K current report · filed Nov 9, 2026

Vir Biotechnology, Inc. (VIR) 8-K Current Report: November 9, 2026

Item 7.01Item 8.01VIR overview

Short answer

Vir Biotechnology, Inc. (VIR) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Vir scheduled a November 9, 2026 investor call to disclose topline Phase 3 ECLIPSE 1 results in chronic hepatitis delta.

Vir Biotechnology, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Vir scheduled a November 9, 2026 investor call to disclose topline Phase 3 ECLIPSE 1 results in chronic hepatitis delta
  • ECLIPSE 1 evaluates monthly subcutaneous elebsiran plus tobevibart, potentially supporting Vir’s lead CHD combination strategy
  • Expanded Phase 2 SOLSTICE data include combination therapy and tobevibart monotherapy, providing additional efficacy and safety context
  • Results webcast available through Vir’s investor website, with 30-day replay access

Item 8.01 · Other Events

  • Phase 3 ECLIPSE 1 primary endpoint met: 44% achieved undetectable HDV RNA plus ALT normalization versus 0% delayed treatment, p<0.0001
  • Key secondary endpoint: 79% achieved undetectable HDV RNA at Week 48 versus 0%, supporting broad antiviral efficacy
  • HDV RNA became undetectable in 85% of cirrhotic patients and 73% of non-cirrhotic patients
  • SOLSTICE Week 96: 100% of 28 patients completing combination therapy reached undetectable viremia
  • Exploratory treatment-free data: 10 patients maintained SVR12 without viral rebound, but interim follow-up remains limited and incomplete

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Vir Biotechnology, Inc. 8-K filings

Get the next VIR 8-K as it lands

Follow VIR for push alerts, or ask the research agent what this filing means.